Hypertension in dialysis patients

Česká verzia

Authors: M. Nedbálková; M. Souček
Authors place of work: II. interní klinika Lékařské fakulty MU a FN u sv. Anny Brno, přednosta doc. MUDr. Miroslav Souček, CSc.
Published in the journal: Vnitř Lék 2008; 54(9): 827-834
Category: Review

Summary

Hypertension in long term dialysis patients has a significant effect on cardiovascular morbidity and the mortality of such patients. Important factors in the pathogenesis of hypertension in dialysis patients include retention of sodium and water, activation of the rennin-angio-tensin system and the sympathetic nervous system, disorders of calcium and phosphate metabolism with osteogenic differentiation of vascular smooth muscle cells and calcification of arteries, vasoactive substance imbalance, endothelium dysfunction and erythropoietin therapy. The basis of treatment is diet with limited salt and fluid intake, restriction of phosphorus in the diet and treatment with phosphate binders, correct dialysis tactics and anti-hypertension medication. Unrestricted salt consumption and a high concentration of sodium in the dialysis solution, alongside reduced residual dieresis, lead to thirst and increased intake of fluids and subsequent water retention. In dialysis it is important to achieve an optimal “dry weight”, i.e. body mass excluding surplus water in the organism. A sufficient length of haemodialysis ensures the removal (ultrafiltration) of excess fluid without episodes of hypotension. If the target blood pressure (< 140/90 mm Hg) cannot be achieved through diet and the maintenance of dry weight, anti-hypertension therapy is used. The optimal choice are blockers for the rennin-angiotensin system: they reduce the mortality of dialysis patients, reduce hypertrophy of the left ventricle, reduce the activity of the sympathetic nervous system, improve endothelial function and reduce oxidative stress. Some anti-hypertension medications (certain ACEIs and beta-blockers) are eliminated by dialysis and it is therefore necessary to adapt the choice of medication and the time of administration. There is a need for further controlled studies to determine the optimal therapy for hypertension in dialysis patients.

Key words:
dialysis treatment – hypertension – diet – dry weight – RAS blockers

Zdroje

1. Hörl MP, Hörl WH. Hemodialysis-associated hypertension: pathophysiology and therapy. Am J kidney Dis 2002; 39: 227–244.

2. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 45(Suppl 3): S1–153.

3. Clinical practice guidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis 2006; 48(Suppl 1): S2–S90.

4. Agarwal R, Nissenson AR, Batlle D et al. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med 2003; 115: 291–297.

5. Levey AS, Beto JA, Coronado BE et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998; 32: 853–906.

6. Wilson J, Shah T, Nissenson AR. Role of sodium and volume in the pathogenesis of hypertension in hemodialysis. Semin Dial 2004; 17: 260–264.

7. Foley RN, Parfrey PS, Harnett JD et al. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int 1996; 49: 1379–1385.

8. Foley RN, Parfrey PS. Cardiovascular disease and mortality in ESRD. J Nephrol 1998; 11: 239–245.

9. Locatelli F, Covic A, Chazot C et al. Hypertension and cardiovascular risk assess-ment in dialysis patients. Nephrol Dial Transplant 2004; 19: 1058–1068.

10. Baumgart P, Walger P, Gemen S et al. Blood pressure elevation during the night in chronic renal failure, hemodialysis and after renal transplantation. Nephron 1991; 57: 293–298.

11. Peixoto AJ, White WB. Ambulatory blood pressure monitoring in chronic renal disease: technical aspects and clinical relevance. Curr Opin Nephrol Hypertens 2002; 11: 507–516.

12. Ritz E, Schwenger V, Zeier M et al. Ambulatory blood pressure monitoring: fancy gadgetry or clinically useful exercise? Nephrol Dial Transplant 2001; 16: 1550–1554.

13. Santos SF, Mendes RB, Santos CA et al. Profile of interdialytic blood pressure in hemodialysis patients. Am J Nephrol 2003; 23: 96–105.

14. Xu J, Li G, Wang P et al. Renalase is a novel, soluble monoamine oxidase that regulates blod pressure. J Clin Invest 2005; 115: 1275–1280.

15. Santos SF, Peixoto AJ. Hypertension in dialysis. Curr Opin Nephrol Hypertens 2005; 14: 111–118.

16. Ketteler M, Floege J. Calcification and the usual suspect phosphate: still guilty but there are other guys behind the scenes. Nephrol Dial Transplant 2006; 21: 33–35.

17. Ketteler M, Westenfeld F, Brandenburg V. The impact of cardiovascular calcifications in chronic kidney disease: Novel pathomechanistic insights. Rev Port Nefrol Hipert 2005; 19(Suppl 1): 41–49.

18. Sobotová D. Hypertenze při chronickém selhání ledvin a pravidelném dialyzačním léčení. KF 2006; 4(4): 36–38.

19. Charra B, Terrat JC, Vanel T et al. Long thrice weekly hemodialysis: the Tassin experience. Int J Artif Organs 2004; 27: 265–283.

20. Foley RN, Herzog CA, Collins AJ. Blood pressure and long‑term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. Kidney Int 2002; 62: 1784–1790.

21. Chazot C, Charra B, Laurent G et al. Interdialysis blood pressure control by long haemodialysis sessions. Nephrol Dial Transplant 1995; 10: 831–837.

22. Charra B, Bergström J, Scribner BH et al. Blood pressure control in dialysis patients: importance of the lag phenomenon. Am J Kidney Dis 1998; 32: 720–724.

23. Kooman J, Basci A, Pizzarelli F et al. EBPG guideline on haemodynamic instability. Nephrol Dial Transplant 2007; 22: ii22–ii44.

24. Tattersall J, Martin-Malo A, Pedrini L et al. EBPG guideline on dialysis strategies. Nephrol Dial Transplant 2007; 22: ii5–ii21.

25. Canaud B, Bragg-Gresham JL, Marshall MR et al. Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS. Kidney Int 2006; 69: 2087–2093.

26. Menon MK, Naimark DM, Bargman JM et al. Long‑term blood pressure control in a cohort of peritoneal dialysis patients and its association with residual renal function. Nephrol Dial Transplant 2001; 16: 2207–2213.

27. Clinical practice guidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis 2006; 48(Suppl): S91–S97.

28. Rocco MV, Frankenfield DL, Prowant B et al. Risk factors for early mortality in U.S. peritoneal dialysis patients: impact of residual renal function. Perit Dial Int 2002; 22: 371–379.

29. Termorshuizen F, Dekker FW, van Manen JG et al. Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. J Am Soc Nephrol 2004; 15: 1061–1070.

30. Efrati S, Zaidenstein R, Dishy V et al. ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis 2002; 40: 1023–1029.

31. Paoletti E, Cassottana P, Bellino D et al. Left ventricular geometry and adverse cardiovascular events in chronic hemodialysis patients on prolonged therapy with ACE inhibitors. Am J Kidney Dis 2002; 40: 728–736.

32. Shibasaki Y, Masaki H, Nishiue T et al. Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron 2002; 90: 256–261.

33. Suzuki H, Kanno Y, Sugahara S et al. Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. Am J Kidney Dis 2004; 43: 1056–1064.

34. Li PK, Chow KM, Wong TY et al. Preservation of residual renal function in peritoneal dialysis patients by angiotensin-converting enzyme inhibitor. A prospective randomized study. J Am Soc Nephrol 2002; 13: F–FC004.

35. Kestenbaum B, Gillen DL, Sherrard DJ et al. Calcium channel blocker use and mortality among patients with end-stage renal disease. Kidney Int 2002; 61: 2157–2164.

36. Foley RN, Herzog CA, Collins AJ. Blood pressure and long‑term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. Kidney Int 2002; 62: 1784–1790.

37. Renal Association. Treatment of adults and children with renal failure: standards and audit measures. 3rd ed. London: Royal College of Physicians of London and the Renal Association, 2002.

38. London GM. Controversy on optimal blood pressure on haemodialysis: lower is not always better. Nephrol Dial Transplant 2001; 16: 475–478.

39. Tozawa M, Iseki K, Iseki C et al. Pulse pressure and risk of total mortality and cardiovascular events in patients on chronic hemodialysis. Kidney Int 2002; 61: 717–726.

40. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ et al. Reverse epidemiology of hypertension and cardiovascular death in the hemodialysis population: the 58th annual fall conference and scientific sessions. Hypertension 2005; 45: 811–817.

41. Conion PJ, Walshe JJ, Heinle SK et al. Predialysis systolic blood pressure correlates strongly with mean 24-hour systolic blood pressure and left ventricular mass in stable hemodialysis patients. J Am Soc Nephrol 1996; 7: 2658–2663.

42. Kooman JP, Gladziwa U, Böcker G et al. Blood pressure during the interdialytic period in haemodialysis patients: estimation of representative blood pressure values. Nephrol Dial Transplant 1992; 7: 917–923.

43. Agarwal R, Lewis RR. Prediction of hypertension in chronic hemodialysis patients. Kidney Int 2001; 60: 1982–1989.

44. Zager PG, Nicolic J, Brown RH et al. “U” curve association of blood pressure and mortality in hemodialysis patients. Kidney Int 1998; 54: 561–569.

45. U.S. Renal Data System: USRDS 1998 Annual Data Report, 1998.

46. Hörl MP, Hörl WH. Hypertension and Dialysis. Kidney Blood Press Res 2003; 26: 76–81.

47. Goodkin DA, Bragg-Gresham JL, Koenig KG et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 2003; 14: 3270–3277.

48. Mazzuchi N, Carbonell E, Fernández-Cean J et al. Importance of blood pressure control in hemodialysis survival. Kidney Int 2000; 58: 2147–2154.